所在地を検索
営業時間、予約なし診療およびご予約。Synonyms
- IDH1
- IDH2
- Isocitrate dehydrogenase 1 and 2
- NADP+
Special Instructions
Please provide a copy of the pathology report. IDH1/2 testing will be delayed if the pathology report is not received. Please direct any questions regarding this test to customer service at 800-345-4363.
Expected Turnaround Time
5 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
Specimen Requirements
Specimen
Whole blood, bone marrow, formalin-fixed, paraffin-embedded (FFPE) tissue block or slides
Volume
3 to 5 mL whole blood, 1 to 2 mL bone marrow, four pre-cut unstained slides at 5 micron with one matching H&E reference slide, or formalin-fixed, paraffin-embedded tissue (FFPE) block
Minimum Volume
3 mL whole blood, 1 mL bone marrow, two unstained slides at 5µm and one matching H&E slide, or three unstained slides at 5µm. Tumor surface area >=4mm2 tumor area and >/= 50% tumor content are preferred
Container
Lavender-top (EDTA) tube, green-top (heparin) tube, yellow-top (ACD) tube, tan-top (K2-EDTA) tube, or pink-top (K2-EDTA) tube FFPE tissue block and slide container
Storage Instructions
Refrigerate. Maintain FFPE blocks/slides at room temperature.
Causes for Rejection
Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage; unsuitable specimens include but are not limited to: frozen whole blood or marrow; a leaking tube; clotted blood or marrow; a grossly hemolyzed specimen or otherwise visibly degraded; specimen suspected of being contaminated by another specimen; specimen contains suspicious foreign material; no tumor tissue in FFPE block or slides; broken or stained slides
Test Details
Use
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes in human cancer. They encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to a-ketoglutarate (aKG), a key component in metabolic and cellular pathways including the Krebs cycle. IDH1 and IDH2 mutations are found in multiple types of human cancer, including but not limited to, acute myeloid leukemia and gliomas. Identification of IDH mutations can aid in their diagnosis, provide prognostic information and suggest treatment with IDH inhibitors. This assay will detect mutations affecting amino acids 100 and 132 of IDH1 and amino acids 140 and 172 of IDH2.
|
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes in human cancer. They encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to a-ketoglutarate (aKG), a key component in metabolic and cellular pathways including the Krebs cycle. IDH1 and IDH2 mutations are found in multiple types of human cancer including, but not limited to, acute myeloid leukemia and gliomas. Identification of IDH mutations can aid in their diagnosis, provide prognostic information, and suggest treatment with IDH inhibitors. This assay will detect mutations affecting amino acids 100, 105, and 132 of IDH1, and amino acids 140 and 172 of IDH2. |
|
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes in human cancer. They encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to a-ketoglutarate (aKG), a key component in metabolic and cellular pathways including the Krebs cycle. IDH1 and IDH2 mutations are found in multiple types of human cancer, including but not limited to, acute myeloid leukemia and gliomas. Identification of IDH mutations can aid in their diagnosis, provide prognostic information and suggest treatment with IDH inhibitors. This assay will detect mutations affecting amino acids 100 and 132 of IDH1 and amino acids 140 and 172 of IDH2. |
Limitations
In vitro studies indicate that this assay has a sensitivity to detect approximately 5% mutated IDH1/2 in a background of non-mutant DNA. Mutations present at a level below the detection sensitivity or outside the analyzed region of the IDH1 and IDH2 genes will not be detected by this assay.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
SNaPshot Multiplex PCR (primer extension-based method)
References
Clark O, Yen K, Mellinghoff IK. Molecular Pathways: Isocitrate dehydrogenase mutations in cancer. Clin Cancer Res. 2016 Apr 15;22(8):1837-1842.26819452
Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016 Apr;27(4):599-608.27005468
Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017 Feb;31(2):272-281.27721426
Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013 Feb 15;19(4):764-772.23209033
US Food & Drug Administration. FDA granted regular approval to enasidenib for the treatment of relapsed or refractory AML. Approved Drugs Web site: https://www.fda.gov/Drugs/InformationonDrugs/ApprovedDrugs/ucm569482.htm. Accessed February 2019.
US Food & Drug Adminstration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. Approved Drugs Web site: https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications. Accessed July 2019.
Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-773.19228619
LOINC® Map
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf